Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC-Reference-Cited by-同舟云学术

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Published:2017-03-31 Issue:9 Volume:109 Page:
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Chaib Imane,Karachaliou Niki,Pilotto Sara,Codony Servat Jordi,Cai Xueting,Li Xuefei,Drozdowskyj Ana,Servat Carles Codony,Yang Jie,Hu Chunping,Cardona Andres Felipe,Vivanco Guillermo Lopez,Vergnenegre Alain,Sanchez Jose Miguel,Provencio Mariano,de Marinis Filippo,Passaro Antonio,Carcereny Enric,Reguart Noemi,Campelo Charo Garcia,Teixido Cristina,Sperduti Isabella,Rodriguez Sonia,Lazzari Chiara,Verlicchi Alberto,de Aguirre Itziar,Queralt Cristina,Wei Jia,Estrada Roger,de la Bellacasa Raimon Puig,Ramirez Jose Luis,Jacobsen Kirstine,Ditzel Henrik J.,Santarpia Mariacarmela,Viteri Santiago,Molina Miguel Angel,Zhou Caicun,Cao Peng,Ma Patrick C.,Bivona Trever G.,Rosell Rafael

Funder

National Natural Science Foundation of China

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/109/9/djx014/19930862/djx014.pdf

Reference23 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;N Engl J Med,2009

2. Signaling networks assembled by oncogenic EGFR and c-Met;Proc Natl Acad Sci U S A.,2008

3. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function;Proc Natl Acad Sci U S A.,2015